Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 21Thoracic 9Breast 7Sarcoma 5Gynecologic 4Genitourinary 4Head & Neck 3Dermatologic 2CNS 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Sarcoma 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Anemia 2Venous Thromboembolism 1Thrombocytopenia 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Fanconi Anemia 1Colonic Neoplasms 1Cachexia 1Breast Neoplasms 1Anorexia 1

Interventions

pegfilgrastim 1Gemcitabine 1Bevacizumab 1ALT-836 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Gemcitabine × Classical hematology × Clear all
NCT01325558 2016-07-15

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Altor BioScience

Phase 1 Completed
30 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡